News

Sapreme Appoints Henrik Luessen as Chief Business Officer

January 21, 2021
Appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer at Sapreme
Read more
Sapreme Appoints Henrik Luessen as Chief Business Officer

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a...
Read more
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

January 12, 2021
Merus N.V. today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness...
Read more
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

ISA106 - SLP therapeutic for COVID-19

January 11, 2021
Interview with ISA Pharmaceuticals' CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cel...
Read more
ISA106 - SLP therapeutic for COVID-19

Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

January 11, 2021
Clinical data from Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of C...
Read more
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

Macrophage Pharma expands Executive team with CSO and CTO

January 09, 2021
Key hires enhance management for next development phase
Read more
Macrophage Pharma expands Executive team with CSO and CTO

Klinische Fase 1a studie met lead compound INT-1B3

January 07, 2021
December 2020: Net voor Kerst in de bijlage van Het Algemeen Dagblad - InteRNA heeft klinische Fase 1a studie met lead compound...
Read more
Klinische Fase 1a studie met lead compound INT-1B3

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

January 07, 2021
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
Read more
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

January 06, 2021
• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 • Evaluation of Cristal's CliCr® and I...
Read more
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

December 17, 2020
Appointment of Björn Cochlovius, Ph.D. as Chairman of the Board
Read more
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

Sapreme Appoints Miriam Bujny as Chief Development Officer

October 27, 2020
Appointment of Miriam Bujny, Ph.D., as Chief Development Officer
Read more
Sapreme Appoints Miriam Bujny as Chief Development Officer

Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

October 15, 2020
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients
Read more
Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

September 30, 2020
positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the O...
Read more
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

September 29, 2020
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of sup...
Read more
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

July 02, 2020
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop...
Read more
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

July 01, 2020
Primes the immune system to attack cancer cells in HPV16-positive cancers
Read more
ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

June 17, 2020
ISA Pharmaceuticals and Regeneron
Read more

CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

May 19, 2020
InteRNA and CATO SMS signed an agreement in which CATO SMS will conduct the Phase I clinical trial with microRNA mimic INT-1B3...
Read more
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

May 11, 2020
Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design
Read more
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

May 06, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced...
Read more
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
1 2 3 4 Next

Home > News > Archive

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds